5HI5

Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.8 Å
  • R-Value Free: 0.219 
  • R-Value Work: 0.201 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists.

Liu, S.Dakin, L.A.Xing, L.Withka, J.M.Sahasrabudhe, P.V.Li, W.Banker, M.E.Balbo, P.Shanker, S.Chrunyk, B.A.Guo, Z.Chen, J.M.Young, J.A.Bai, G.Starr, J.T.Wright, S.W.Bussenius, J.Tan, S.Gopalsamy, A.Lefker, B.A.Vincent, F.Jones, L.H.Xu, H.Hoth, L.R.Geoghegan, K.F.Qiu, X.Bunnage, M.E.Thorarensen, A.

(2016) Sci Rep 6: 30859-30859

  • DOI: 10.1038/srep30859
  • Primary Citation of Related Structures:  5HI3, 5HI4

  • PubMed Abstract: 
  • Interleukin-17A (IL-17A) is a principal driver of multiple inflammatory and immune disorders. Antibodies that neutralize IL-17A or its receptor (IL-17RA) deliver efficacy in autoimmune diseases, but no small-molecule IL-17A antagonists have yet progr ...

    Interleukin-17A (IL-17A) is a principal driver of multiple inflammatory and immune disorders. Antibodies that neutralize IL-17A or its receptor (IL-17RA) deliver efficacy in autoimmune diseases, but no small-molecule IL-17A antagonists have yet progressed into clinical trials. Investigation of a series of linear peptide ligands to IL-17A and characterization of their binding site has enabled the design of novel macrocyclic ligands that are themselves potent IL-17A antagonists.


    Organizational Affiliation

    Worldwide Medicinal Chemistry, Pfizer Worldwide R&D, Eastern Point Road, Groton, CT 06340, USA.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
Interleukin-17A
A, B
132Homo sapiensGene Names: IL17A (CTLA8, IL17)
Find proteins for Q16552 (Homo sapiens)
Go to Gene View: IL17A
Go to UniProtKB:  Q16552
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
CAT-2000 FAB heavy chain
C, H
237N/AN/A
Protein Feature View is not available: No corresponding UniProt sequence found.
Entity ID: 3
MoleculeChainsSequence LengthOrganismDetails
CAT-2000 light chain
D, L
214N/AN/A
Protein Feature View is not available: No corresponding UniProt sequence found.
Entity ID: 4
MoleculeChainsSequence LengthOrganismDetails
synthetic IL-17A inhibitor
I
16N/AN/A
Protein Feature View is not available: No corresponding UniProt sequence found.
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
63Q
Query on 63Q

Download SDF File 
Download CCD File 
B
(4S,20R)-7-chloro-N-methyl-4-{[(1-methyl-1H-pyrazol-5-yl)carbonyl]amino}-3,18-dioxo-2,19-diazatetracyclo[20.2.2.1~6,10~.1~11,15~]octacosa-1(24),6(28),7,9,11(27),12,14,22,25-nonaene-20-carboxamide
C33 H33 Cl N6 O4
CEFRORFLEYHRHI-IZLXSDGUSA-N
 Ligand Interaction
Modified Residues  1 Unique
IDChainsTypeFormula2D DiagramParent
ACE
Query on ACE
I
NON-POLYMERC2 H4 O

--

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.8 Å
  • R-Value Free: 0.219 
  • R-Value Work: 0.201 
  • Space Group: P 1 21 1
Unit Cell:
Length (Å)Angle (°)
a = 91.320α = 90.00
b = 68.680β = 90.65
c = 100.530γ = 90.00
Software Package:
Software NamePurpose
PHASERphasing
AutoPROCdata scaling
Aimlessdata scaling
BUSTERrefinement

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2016-01-11 
  • Released Date: 2016-08-31 
  • Deposition Author(s): Liu, S.

Revision History 

  • Version 1.0: 2016-08-31
    Type: Initial release
  • Version 1.1: 2017-11-22
    Type: Derived calculations, Refinement description